Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US ...

Xospata was cleared in the US and Japan last year, and the CHMP backing gives Astellas another leg up in the market over Daiichi Sankyo and its FLT3 inhibitor quizartinib. The EMA is also in the ...

为解决 FLT3 突变的急性髓系白血病（AML）治疗耐药问题，研究人员开展 FHD-286 与 FLT3 抑制剂联合治疗研究，发现联合治疗增效显著，有重要临床意义。 为了攻克这一难题，美国德克萨斯大学 MD 安德森癌症中心（The University of Texas M.D. Anderson Cancer Center）的研究人员展开了深入研究。他们的研究成果发表在《Blood Cancer ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells ...

Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease IPG222 27 June 2007 27 June 2007 Carmustine implants and ...

Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures CG64 17 March 2008 8 July 2016 ...

Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc., financial results conference call. (Operator Instructions) Please note this call is being recorded. It is now my pleasure to ...

Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc. Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the ...